Laekna, Inc.

来凯医药有限公司

02105.HK

Clinical-stage biotechnology company developing oncology drug candidates, including an AKT inhibitor and an androgen synthesis inhibitor for ovarian, prostate and breast cancers, with two core products in-licensed from Novartis and six ongoing clinical trials.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Supplier concentration
• Reliance on platforms, partners or licences
• Outsourced production (OEM / contract manufacturing)
• Losses and path to profitability
• Cash burn and runway
• Goodwill, intangibles and asset impairment
• Preferred shares and fair-value liabilities
• Non-recurring gains and losses
• Chapter 18A biotech